ABSTRACT
Purpose:To investigate the efficacy of infusion gemcitabine via artery port and catheter system (PCS) for advanced pancreatic cancer.Methods:57 cases advanced pancreatic cancer proved by pathology were implanted Implantofix PCS.The number of ports implanted subcutaneously in inferior right abdomen and subcutanceusly in inferior chest was 48 and 9 cases respectively.The first total does in experience group was gemcitabine 3.0,5-FU 3.0,IL-2 6 million u via three times infusion.Results:The overall implanted successful rates was 100% and indwelling catheter tip dislocation rate was 0. Two PCS were pulled out in 2 fat old female patients because of bad wound healing after two months.In the experimental and control group according to the standard of clinical benefit-responces were 37 and 20 respectively.The obvious improve- ment in pain in experimental and control group was 27.2% and 4.8%,respectively.The duration of clinical benefit-re- sponces were 18 weeks in experimental groups,13 weeks in control group.The midian survival in experimental group was 6.25 months,4.41 months in control group.The 6-,9-,12-months survival rates in experimental group were 46%,24%, 18% more thans 31%,6% and 2% in control group.Conclusions:Infusion gemcitabine via artery PCS can not only relieve pain,prolong survival rate but also provides a long-term intra-arterial chemotherapy and effctive access for advanced pancre- atic cancer.
ABSTRACT
Objective To preliminarily investigate curative effect of hepatic arterial perfusion of p53 gene in the therapy of advanced hepatocellular carcinoma.Methods Tirty cases of advanced hepatocellular carcinoma were divided into experimental group and control group,p53 gene was perfused into target artery confirmed by angiography.In experimental group,10~(12)Vp of p53 gene and 20 mg OPT were employed every week as a course for 21 days and 1 to 4 courses time the cases of the study.In control group,only 20 mg OPT was used.Results The survival period was 14 to 405 days in experimental group and 18 to 167 days in control group.There was a significant difference between the two groups(P＜0.05). Conclusion p53 gene is efficacious in the therapy of advanced hepatocellular carcinoma.(J Intervent Radiol,2007,16:127-129)